Protease inhibitors (PIs) are potent antiretroviral agents, although their rapid intestinal and hepatic metabolism, mainly by the cytochrome P450 pathway, leads to a low systemic exposure. Boosting PIs has had a significant impact on the treatment of type-1 human immunodeficiency virus (HIV-1) infection by improving their pharmacokinetic profile, resulting in more durable efficacy, higher barrier to resistance, reduced pill burden and dosing frequency [1].
Conclusion:Trough 48 weeks, switching DRV/RTV to DRV/COBI is safe and maintains viral efficacy, without significant changes in lipid profile or renal function.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.